AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Rare metaplastic breast malignancies often reveal extensive vascularity.

Women's Health Weekly

| May 08, 2003 | COPYRIGHT 2003 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

2003 MAY 8 - (NewsRx.com & NewsRx.net) -- Rare metaplastic breast malignancies often reveal extensive vascularity.

According to recent research from Italy, "Metaplastic breast carcinomas are rare neoplasms showing both carcinomatous and sarcomatous elements. In this report we describe eleven cases of metaplastic breast carcinoma focusing on pathological features and the clinical behavior of six patients with breast carcinoma with chondroid metaplasia (MCC). We collected eleven cases from 1996 to 2001: immunohistochemical tests were performed in order to obtain data on estrogen and progesterone receptors and the production of p53 gene and HER/2 neu."

"Neoangiogenesis was studied counting vessels immunohistochemically stained with CD31 antibody. Six cases showed chondroid metaplasia, three cases were spindle cell carcinoma and two were metaplastic squamous carcinoma," stated R. Bellino and colleagues, University of Turin.

"The majority of patients (64%) had pT2 tumors without axillary node metastases: only two cases with spindle or squamous metaplasia showed nodal involvement. Fifty percent of MCC were pT1b-c tumors: no axillary metastases were observed."

"Vascular invasion was observed in all squamous and spindle cell types and in 66% of MCC: estrogen and progesterone receptors were absent in 90% of the tumors," said researchers.

"Immunohistochemical staining for HER2/neu was detected in 72% of spindle cell and squamous carcinomas and in 33% of MCC. Three cases staining highly for p53 were chondroid carcinomas: the staining was uniform both in carcinomatous and in sarcomatous tissue. The ...

Related articles from newspapers, magazines, journals, and more
Metaplastic breast carcinoma with osseous differentiation: a case report.(Case...
Magazine article from: Southern Medical Journal Pollock, Jeffrey M. Green, Allan Donnell, Cynthia Dyess, Donna Lynn Tucker, J. Allan February 1, 2006 700+ words
Abstract: Metaplastic breast carcinoma is a rare entity...patient found to have a rare metaplastic breast carcinoma with prominent osseous...correlation is provided. Key Words: metaplastic breast carcinoma, osseous differentiation...
An unusual case of metaplastic breast carcinoma (sarcomatoid variant).(Case...
Magazine article from: Indian Journal of Surgery Alam, Kiran Maheshwari, Veena Harris, Hasan Mehdi, Ghazala July 1, 2003 700+ words
...Broadly, there are four variants of metaplastic breast carcinoma: the sarcomatoid type...carcinoma. In the sarcomatoid type of metaplastic breast carcinoma, which was the variety...for multiple breast components as metaplastic breast carcinoma, especially the sarcomatoid...
Alfacell's ONCONASE Study Results Published In Anticancer Research.
Press release article from: M2 Presswire March 26, 2007 700+ words
...Watchlist: Alfacell's ONCONASE Study Results Published In Anticancer Research(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:26032007...cell lung cancer (NSCLC) were recently published in Anticancer Research. "ONCONASE has important potential clinical uses for...
Data Published in Anticancer Research Show ChemoFx(R) Assay Results Correlate...
Press release article from: PR Newswire July 1, 2008 700+ words
...response in breast cancer patients treated with neoadjuvant (pre-operative) chemotherapy. Data published in Anticancer Research show that the assay accurately predicted response to therapy 75% of the time. This study, done in conjunction...
Functional nuclear MRI is applied to in vivo anticancer research.
Newspaper article from: Cancer Weekly June 29, 2004 700+ words
...of Radiology (The development and application of functional nuclear magnetic resonance to in vivo therapeutic anticancer research. Br J Radiol, 2004;77(916):296-307). For more information, contact A. Dzikjurasz, GlaxoSmithKline...
Making The Watchlist: Alfacell's ONCONASE Study Results Published In Anticancer...
News wire article from: Europe Intelligence Wire March 26, 2007 700+ words
...ONCONASE (ranpirnase) for the treatment of non-small cell lung cancer (NSCLC) were recently published in Anticancer Research. "ONCONASE has important potential clinical uses for the treatment of NSCLC," said Dr. Lee. "We are pleased...
In vivo Study Results Demonstrating Potential of Alfacell's ONCONASE(R) for...
Press release article from: PR Newswire March 26, 2007 700+ words
...ONCONASE (ranpirnase) for the treatment of non-small cell lung cancer (NSCLC) were recently published in Anticancer Research (2007; 27: 299- 308). Based on the work of Intae Lee, Ph.D., at the University of Pennsylvania, a...
Two firms join in anticancer research. (Magainin Pharmaceuticals Inc./Sandoz...
Newspaper article from: Cancer Weekly January 18, 1993 700+ words
DATELINE: Magainin Pharmaceuticals/Sandoz Pharmaceuticals Magainin Pharmaceuticals Inc., Plymouth Meeting, Pennsylvania, and Sandoz Pharmaceuticals Corporation, East Hanover, New Jersey, have signed an agreement to develop anticancer drugs. Jay Moorin, president of Magainin, said his company has
Strawberry fields (funding) forever.(Indications)(anticancer research)(Brief...
Magazine article from: Family Practice News Kubetin, Sally Koch June 15, 2005 700+ words
Forget your concern that funding from the pharmaceutical industry may influence medical research findings. Now fruit farmers have joined the action, underwriting research into the health benefits of their produce. Specifically, the University of California, Los Angeles, has received a grant from
CHIMIE HEBDO: AstraZeneca licenses protein for anticancer research.
News wire article from: Chemical Business Newsbase May 14, 2001 700+ words
AstraZeneca has paid $12 M for a licence from the US company Cyclacel to use work done by Cyclacel on the p53 protein. AstraZeneca hopes to use analogues of p53 to develop a new cancer treatment. The group is to pay Cyclacel as the work progresses, and also royalties from the sales of any products
For more facts and information, see all results

Source: HighBeam Research, Rare metaplastic breast malignancies often reveal extensive...

©2009 Gale, a part of Cengage Learning. All rights reserved.
About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA